Evidence map›Paper›PMID 42698001›Full record

ArticleNature metabolism2026

UBE2N deficiency contributes to MASH development via p62-regulated mitophagy and PANoptosis.

Feng Wang, Jin Lee, Jeong-Su Park, Meizhou Huang, Hwan Ma, Guoyan Sui, Zixiong Zhou, Michitaka Matsuda, So Yeon Kim, Takashi Tsuchiya and 11 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Feng Wang *College of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju, South Korea.
Jin Lee *Department of Pathology, School of Medicine, University of California, San Diego, La Jolla, CA, USA.
Jeong-Su Park *College of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju, South Korea.
Meizhou Huang *Metabolic Hepatobiliary and Pancreatic Diseases Key Laboratory of Luzhou City, Department of General Surgery, The Affiliated Hospital, Southwest Medical University, Sichuan, China.
Hwan MaCollege of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju, South Korea.
Guoyan SuiCollege of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju, South Korea.
Zixiong ZhouDepartment of Pathology and Institute of Oncology, The School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.ORCID http://orcid.org/0009-0006-6677-1432
Michitaka MatsudaKarsh Division of Gastroenterology and Hepatology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
So Yeon KimKarsh Division of Gastroenterology and Hepatology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Takashi TsuchiyaKarsh Division of Gastroenterology and Hepatology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Xuefeng WuShanghai Institute of Immunology, Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID http://orcid.org/0000-0002-6933-7280
Haram LeeCollege of Pharmacy, Korea University, Sejong, South Korea.ORCID http://orcid.org/0000-0002-3175-0336
Soohwan OhCollege of Pharmacy, Korea University, Sejong, South Korea.
Hanseul ParkCollege of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju, South Korea.
Key-Hwan LimCollege of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju, South Korea.
Chun-Woong ParkCollege of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju, South Korea.
Sang-Bae HanCollege of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju, South Korea.
Jin Tae HongCollege of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju, South Korea.
Michael KarinDepartment of Pharmacology, University of California, San Diego, La Jolla, CA, USA.
Yoon Seok RohCollege of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju, South Korea. ysroh@cbnu.ac.kr.ORCID http://orcid.org/0000-0002-6689-177X
Ekihiro SekiKarsh Division of Gastroenterology and Hepatology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA. ekihiro.seki@csmc.edu.ORCID http://orcid.org/0000-0002-9472-6085

Funding

LPS binding to TLR4 regulates hepatic stellate cell activation and fibrosisR01DK085252 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI EKIHIRO SEKI · 2011 to 2026
$4.8M
Determination of Molecular Mechanism of Stellate Cell-Mediated FibrosisR01DK138591 · NIDDK · CEDARS-SINAI MEDICAL CENTER · PI EKIHIRO SEKI · 2024 to 2026
$1.7M
Steatotic Liver Promotes Metastatic Niche: Role of Hepatic Stellate CellsR01CA301632 · NCI · CEDARS-SINAI MEDICAL CENTER · PI EKIHIRO SEKI · 2025 to 2026
$1.3M
American Association for the Study of Liver Diseases (AASLD) Pinnacle Research Award of AASLDFoundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) R01CA301632Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) R01DK085252Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) R01DK138591National Natural Science Foundation of China (National Science Foundation of China) 82404726National Research Foundation of Korea (NRF) RS-2025-02273102National Research Foundation of Korea (NRF) RS-2025-02603096NCI NIH HHS R01 CA301632NIDDK NIH HHS R01 DK085252NIDDK NIH HHS R01 DK138591
6 · The paper itself

Abstract

K63-linked ubiquitination (K63) is closely associated with the interaction, intracellular trafficking or activity of tagged proteins. However, its role during metabolic dysfunction-associated steatohepatitis (MASH) is largely unknown. Here we show that UBE2N, a ubiquitin-conjugating enzyme that specializes in creating K63, is downregulated by THAP11 in human and mouse hepatocytes with MASH. While hepatocyte-specific Ube2n deficiency exacerbates western diet-induced MASH and fibrosis via PANoptosis and impaired mitophagy, its overexpression reverses these pathological phenotypes and restores hepatic homeostasis. Mechanistically, UBE2N increases PARKIN-mediated K63-p62 at lysine 420, promoting K63-p62 translocation into damaged mitochondria for mitophagic clearance. Ube2n deficiency, conversely, induces cytoplasmic p62 accumulation and NRF2 hyperactivation, driving PANoptosis. Additional Sqstm1 deletion mitigates Ube2n deletion-induced pathologies, highlighting the importance of p62 accumulation for MASH progression. Thus, our results demonstrate that hepatocyte UBE2N is essential for regulation of metabolic stress-mediated mitophagy and PANoptosis, and that p62 is a proof-of-concept target for treating MASH and fibrosis.

Indexed as

Fatty LiverMitophagySequestosome-1 ProteinUbiquitin-Conjugating EnzymesAnimalsHepatocytesHumansMaleMiceMitochondriaUbiquitin-Protein LigasesSequestosome-1 ProteinUbiquitin-Conjugating EnzymesUbiquitin-Protein Ligases

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.